Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2412. 2012 Authors' conclusions Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension is recommended as an option for use within NHS Wales for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children. Indexing Status Subject indexing assigned by CRD MeSH 6-Mercaptopurine; Administration, Oral; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000875 Date abstract record published 26/11/2012 |
